Metformin for Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase-Based Progress Estimates
Effectiveness
Safety
Heart Failure With Preserved Ejection Fraction (HFpEF)+1 More
Metformin - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial will study the effects of metformin on heart failure patients with preserved ejection fraction.
Eligible Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
Treatment Effectiveness
Effectiveness Progress
Other trials for Heart Failure With Preserved Ejection Fraction (HFpEF)
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Week 20
Week 20
6-minute walk distance (6MWD)
C-reactive protein
Fecal Mucin
Interleukin-6
Cardiomyopathies
Lipopolysaccharide binding protein (LBP)
Peak VO2
Short Physical Performance Battery (SPPB)
Tumor necrosis factor-alpha
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Other trials for Heart Failure With Preserved Ejection Fraction (HFpEF)
Trial Design
2 Treatment Groups
Metformin
1 of 2
Placebo
1 of 2
Active Control
Non-Treatment Group
80 Total Participants · 2 Treatment Groups
Primary Treatment: Metformin · Has Placebo Group · Phase 2
Metformin
Drug
ActiveComparator Group · 1 Intervention: Metformin · Intervention Types: DrugPlacebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 20
Who is running the clinical trial?
Wake Forest University Health SciencesLead Sponsor
1,113 Previous Clinical Trials
1,129,589 Total Patients Enrolled
2 Trials studying Heart Failure With Preserved Ejection Fraction (HFpEF)
880 Patients Enrolled for Heart Failure With Preserved Ejection Fraction (HFpEF)
University of South FloridaOTHER
367 Previous Clinical Trials
100,074 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,380 Previous Clinical Trials
3,446,676 Total Patients Enrolled
5 Trials studying Heart Failure With Preserved Ejection Fraction (HFpEF)
985 Patients Enrolled for Heart Failure With Preserved Ejection Fraction (HFpEF)
Dalane W. Kitzman, MDPrincipal InvestigatorWake Forest University Health Sciences
2 Previous Clinical Trials
429 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:This study is evaluating whether a new definition of heart failure with preserved ejection fraction (HFpEF) will improve the ability to identify people with heart failure who are at high risk of dying.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments